Is tight glycemic control in type 2 diabetes really worthwhile?: YES
Clement M et al. - Since the first big landmark trial on glycemic control and complications in type 1 diabetes (DCCT [Diabetes Control and Complications Trial]) was published in 1993, almost every major trial for type 1 and type 2 diabetes has consistently demonstrated the beneficial effects of lowering glucose on diabetes complications.
- Diabetes trials have consistently shown that lower hemoglobin A1c levels decrease complications of the disease.
- Longer trials, such as the DCCT and the EDIC follow-up, the UKPDS, and the Steno-2 Study, have demonstrated the additional macrovascular benefits of tight glycemic control.
- The "legacy" effect of tight control at an earlier stage of disease has a lasting influence on the reduction of both microvascular and macrovascular complications.
- The ACCORD trial findings should not be generalized to younger, healthier patients.
[more...]
|
|
|
